Emcure Pharmaceuticals Limited has informed the Exchange regarding 'Intimation under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Submission of application for seeking re-classification from the Promoter and Promoter Group category to Public category'.
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than Nifty Smallcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Emcure Pharmaceuticals has filed an application with BSE and NSE to re-classify 29 entities (individuals, trusts, and companies) from the 'Promoter and Promoter Group' category to the 'Public' category. The list includes members of the Shah family, Bharadwaj family, Thapar family, various trusts, and private limited companies. Importantly, the filing explicitly states that these applicants are not holding any Equity Shares of the Company. The re-classification is sought under SEBI Listing Regulations and follows an earlier communication dated June 21, 2025.
This is a procedural/housekeeping filing with no direct impact on shareholding or stock price, as the entities being re-classified do not hold any shares. It simply removes non-shareholding related parties from the promoter group list for regulatory clarity.